BCM
VKTX icon

Bayesian Capital Management’s Viking Therapeutics VKTX Stock Holding History

Bayesian Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,100
Closed -$633K – 537
2025
Q3 		$633K Buy
24,100
+7,900
+49% +$236K 0.13% 235
2025
Q2 		$429K Buy
+16,200
New +$426K 0.07% 317
2024
Q4 		– Sell
-4,200
Closed -$266K – 1018
2024
Q3 		$266K Buy
+4,200
New +$246K 0.03% 503
2023
Q3 		– Sell
-16,664
Closed -$270K – 1024
2023
Q2 		$270K Buy
+16,664
New +$349K 0.03% 567
2021
Q2 		– Sell
-12,800
Closed -$81K – 659
2021
Q1 		$81K Buy
+12,800
New +$90.1K 0.02% 499
2018
Q4 		– Sell
-11,600
Closed -$202K – 801
2018
Q3 		$202K Buy
+11,600
New +$138K 0.03% 566

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return